KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Long-Term Deferred Tax (2019 - 2026)

GoodRx Holdings' Long-Term Deferred Tax history spans 6 years, with the latest figure at $57.1 million for Q4 2025.

  • On a quarterly basis, Long-Term Deferred Tax fell 26.0% to $57.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $57.1 million, a 26.0% decrease, with the full-year FY2025 number at $57.1 million, down 26.0% from a year prior.
  • Long-Term Deferred Tax hit $57.1 million in Q4 2025 for GoodRx Holdings, down from $69.1 million in the prior quarter.
  • Over the last five years, Long-Term Deferred Tax for GDRX hit a ceiling of $77.2 million in Q4 2024 and a floor of $13.0 million in Q2 2021.
  • Historically, Long-Term Deferred Tax has averaged $58.0 million across 4 years, with a median of $65.3 million in 2023.
  • Biggest five-year swings in Long-Term Deferred Tax: skyrocketed 2616.3% in 2021 and later decreased 26.0% in 2025.
  • Tracing GDRX's Long-Term Deferred Tax over 4 years: stood at $45.8 million in 2021, then surged by 42.43% to $65.3 million in 2023, then rose by 18.25% to $77.2 million in 2024, then dropped by 26.0% to $57.1 million in 2025.
  • Business Quant data shows Long-Term Deferred Tax for GDRX at $57.1 million in Q4 2025, $69.1 million in Q3 2025, and $77.2 million in Q2 2025.